DSIP: A Name Is Not a Sleep Guarantee
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Delta sleep-inducing peptide, or DSIP, has a name that sounds like a finished explanation. It began as a research finding in rabbits in the 1970s. Researchers linked the peptide with changes in slow-wave electrical activity. Translating that finding into a dependable treatment for human insomnia proved much less straightforward. A double-blind study in sixteen people with chronic insomnia found limited changes and no improvement in subjective sleep quality. The authors did not see major therapeutic benefit. DSIP’s physiology and clinical usefulness remain unresolved in this evidence. FDA also describes safety-data gaps. An evocative name does not establish better sleep, a clear mechanism, or a safe treatment.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Schoenenberger and Monnier (1977): Characterization of a delta-EEG-inducing peptide
https://pubmed.ncbi.nlm.nih.gov/265572/
Primary animal discovery study

[2] Effects of DSIP on sleep of chronic insomniac patients: a double-blind study
https://pubmed.ncbi.nlm.nih.gov/1299794/
Primary small human trial

[3] FDA peptide safety information: Emideltide (DSIP)
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator

EVIDENCE LIMITATIONS
The early trial is small and cannot provide a definitive modern efficacy estimate.
Do not treat an animal EEG effect as a validated treatment for chronic insomnia.
Older positive uncontrolled reports do not resolve inconsistent controlled evidence.
Avoid claims of a fully established DSIP-specific sleep mechanism.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1945984319692823/